I wanted to know if any of you know an excellent asthma specialist in the new york city area. The cf clinics can only do so much with severe asthma issues. Need to have someone who really understands asthma and all it's complications. Any suggestions would be appreciated. thanks
Cystic fibrosis (CF) is characterized by inflammation, progressive lung disease, and respiratory failure. Although the relationship is not well understood, patients with CF are thought to have a higher prevale...
CONCLUSION: Our results did not show that S. aureus found in nasal mucosa membrane is significantly different in patients with or without NP. However, association of the presence of S. aureus in patients with nasal polyposis with asthma, allergy and inflammation has been shown. PMID: 31785225 [PubMed - as supplied by publisher]
In this study, OVA-sensitized/challenged mice were treated with AZM after inoculation with RSV. We found that AZM treatment not only suppressed AHR, but also reduced all key markers of exacerbation. Furthermore, TNFa-produced by alveolar macrophages was reduced with AZM treatment. Recombinant TNFa administration could reverse exacerbation in the presence of AZM. Our findings highlight the mechanism of AZM suppressed AHR and airway inflammation in RSV-induced asthma exacerbation through targeting the innate immune response linked to alveolar macrophages and TNFa production.
We present a 23-year-old male with a history of cystic fibrosis (CF) with associated renal disease, bronchiectasis, pneumothorax, and distal intestinal obstruction syndrome admitted for CF exacerbation. Sputum culture was positive for methicillin resistant Staphylococcus aureus (MRSA). Chest imaging revealed extensive opacities in the left lung. His FEV1 during admission was 52% (baseline 70%). Allergy was consulted as inhaled vancomycin therapy was preferred, but the patient had previous vancomycin-induced reactions.
High antibiotic utilization is an essential element of life-saving care for cystic fibrosis (CF) patients. However, adverse drug reactions (ADRs) to antibiotics occur more commonly and discrete types of ADRs may differ in CF patients compared to the general population. Characterization of documented ADRs among CF patients is needed in order understand how antibiotic utilization can be improved for CF patients.
Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF), representing a significant clinical challenge. It is especially a concern in the pediatric population given adverse effects of steroids in this population. Here we report on the use of omalizumab in the treatment of steroid-resistant ABPA in a pediatric patient with CF.
BackgroundChronic rhinosinusitis (CRS) is associated with bronchiectasis; however, this relationship has not been well studied in the United States (US) population. In this work we aimed to determine the prevalence of CRS among patients with bronchiectasis affiliated with a US tertiary medical center and identify which comorbid diseases are associated with the presence of CRS in patients with bronchiectasis.MethodsThis was a retrospective cohort study in which data were obtained from a large database warehouse at a tertiary care center. Patients with bronchiectasis were identified from 2007 to 2017 using diagnosis codes fr...
This study assessed omalizumab outcomes in real-world patients with allergic asthma stratified by pretreatment biomarker levels. METHODS: Patients with allergic asthma aged ≥12 years initiated on omalizumab with ≥12 months of data after index were identified in the Allergy Partners electronic medical records (2007-2018). Patients with ≥1 diagnosis of chronic obstructive pulmonary disease in combination with ≥10 pack-years of smoking, cystic fibrosis, Alpha-1 antitrypsin deficiency, bronchiectasis, interstitial lung disease, and sarcoidosis in the 12 months before or after index were excluded. Patients were...
Polymyxins, namely colistimethate sodium (colistin or polymyxin E) and polymyxin B, are used for multi-drug resistant gram-negative bacterial infections, including Pseudomonas aeruginosa and Acinetobacter baumannii 1. As treatments and therapy have advanced, patients with cystic fibrosis are living longer. However, these patients have high exposure to intravenous antibiotics, most commonly penicillins, cephalosporins, and aminoglycosides. With colonization or infections with resistant gram-negative bacilli, the exposure to antibiotics broadens to include the polymyxins.
The type I receptor for advanced glycation end-products (RAGE) belongs to the immunoglobulin superfamily and is abundantly expressed in the lungs, notably in type 1 alveolar epithelial cells.1 As such, RAGE has been implicated in lung development and in the pathogenesis of chronic lung diseases ranging from cystic fibrosis to asthma.1